Abstract
Background:
The definition of health for people with cancer is not focused solely on the physiology of illness and the length of life remaining, but is also concerned with improving the well-being and the quality of the life (QOL) remaining to be lived. This study aimed to identify the constructs most associated with QOL in people with advanced cancer.
Methods:
Two hundred three persons with recent diagnoses of different advanced cancers were evaluated with 65 variables representing individual and environmental factors, biological factors, symptoms, function, general health perceptions and overall QOL at diagnosis. Three independent stepwise multiple linear regressions identified the most important contributors to overall QOL. R2 ranking and effect sizes were estimated and averaged by construct.
Results:
The most important contributor of overall QOL for people recently diagnosed with advanced cancer was social support. It was followed by general health perceptions, energy, social function, psychological function and physical function.
Conclusions:
We used effect sizes to summarise multiple multivariate linear regressions for a more manageable and clinically interpretable picture. The findings emphasise the importance of incorporating the assessment and treatment of relevant symptoms, functions and social support in people recently diagnosed with advanced cancer as part of their clinical care.
Similar content being viewed by others
Main
Cancer will develop in 45% of men and 40% of women during their lifetime, and about 1 in 4 will die of the disease (Marrett et al, 2008). The survival rates for most tumours are, however, continually improving owing to earlier detection, continued improvement in treatment therapies and better general medical management (Marrett et al, 2008). Owing to its improved survival, cancer is now considered a chronic disease (Canadian Academy of Health Sciences, 2010), and as a result, concerns about the well-being and the quality of life (QOL) of people with cancer has become paramount in clinical research (Food and Drug Administration, 2006). Health-care professionals are also becoming increasingly exposed to the benefits of assessing QOL in daily clinical practice. But the understanding of the scientific basis underlying QOL assessment still needs to be established (Osoba, 2007).
A comprehensive model of health-related QOL (HRQL) was developed by Wilson and Cleary (1995). This conceptual model suggests causal links among biological and physiological factors, symptoms, functional levels, general health perceptions and overall QOL. Individual and environmental characteristics also influence each of the components of the model (Wilson and Cleary, 1995). The Wilson and Cleary Model of HRQL for people with cancer can be seen in Figure 1.
The Wilson and Cleary model was partly assessed for patients with gastrointestinal bleeding (Sousa and Williamson, 2003), Parkinson’s disease (Straits-Troster et al, 2000; Chrischilles et al, 2002), heart disease (Bennett et al, 2001; Heo et al, 2005; Lee et al, 2005a; Mathisen et al, 2007), HIV/AIDS (Wilson and Cleary, 1996, 1997; Sousa et al, 1999; Cosby et al, 2000; Hays et al, 2000; Sousa and Chen, 2002; Cunningham et al, 2005; Sousa and Kwok, 2006), renal disease (Molzahn et al, 1996). It was minimally examined in people with cancer, as only one study examined the model with survivors with Hodgkin’s lymphoma (Wettergren et al, 2004).
The purpose of this study was therefore to estimate, for people with a newly diagnosed advanced cancer, the extent to which biological and physiological factors, symptoms, function and general health perceptions predict overall QOL, as hypothesised by the Wilson and Cleary Model of HRQL.
Material and methods
Participants
Adults were recruited if they have had a recent diagnosis of advanced cancer and had been referred to the McGill University Health Center or the Jewish General Hospital oncology clinics, in Montreal, Canada. Advanced cancer was defined as unresectable stage 3A, 3B or 4 non-small-cell lung cancer; stage 3 or 4 upper gastrointestinal cancer; stage 4 colorectal, hepatobilliary or head and neck cancers; breast and prostate cancers with visceral metastases; and all stages of pancreatic cancers. The inclusion criterion included an estimated life expectancy of 3 months or more and an Eastern Cooperative Oncology Group Performance Status Score of 0 to 3 to represent varying degrees of disabilities but sufficient function to complete the assessments (Oken et al, 1982). Patients were not eligible if they were unable to comply with study instructors or if they had symptomatic brain metastases.
Procedure
The study was approved by the hospitals’ Institutional Review Board. The eligibility of patients was verified by a member of their primary oncology team who also obtained verbal consent to be approached by study personnel. If patients consented to participate, an appointment was made for the assessment. At their first assessment, participants were assessed using patient-reported outcomes and direct measures representing the domains of the Wilson and Cleary conceptual model of HRQL. If patients refused to participate, sociodemographic information such as their age, their primary tumour origin and their gender were collected, as were their self-perceived health from 0 to 10. This was done to estimate whether there was a sampling bias between participants and non-participants.
Measurement
The measurement strategy included characterising the sample and selecting relevant items and domains from widely used health outcomes measures in cancer.
The outcome of interest in this study was the construct of overall QOL. One subscale and two single items were used to represent overall QOL: the existential domain of the McGill Quality Of Life Questionnaire (MQOL-existential), the single-item scale of the McGill Quality of Life Questionnaire (MQOL-SIS) and the QOL item of the Edmonton Symptom Assessment System (first version) (ESAS-QOL).
Fifty-seven explanatory variables and eight potential confounder variables were included in the analyses. The variables were chosen to represent the different domains of the Wilson and Cleary model. The measures used and their psychometric properties are fully described in the Appendices A and B (Table A1 and A2), recognising that the individual items and subscales were the elements used in the analyses.
Biological and physiological indicators were also collected. These included C-reactive protein serum concentration levels, recent recalled weight loss at the time of diagnosis, the body mass index, the skeletal muscle index and the presence of sarcopenia.
In addition, personal factors such as age, sex, the site of the original tumour, the number of comorbidities, the highest level of education completed and the country of birth were recorded on the day of testing. Social environmental characteristics were also collected, such as the marital status and the number of children.
Statistical methods
Three different subscale/items (MQOL-existential, MQOL-SIS and ESAS-QOL) represented the outcome construct, overall QOL. Consequently, three independent analyses were performed to determine the most important contributors of overall QOL.
Descriptive statistics were used to characterise the participants and the distribution of variables. Mean values and standard deviations for continuous variables, as well as frequencies and percentages for categorical variables, summarised patients’ characteristics. Age, sex, primary tumour site, years of education, cultural origin, number of comorbidities, number of children and marital status were examined for their potential for confounding.
Univariate linear regressions were used to screen the associations between the 57 potential contributors to each representation of overall QOL. Variables that were associated with one of the QOL measures at P-value below or equal the 0.1 level were retained for the further analyses.
Bivariate correlations between the retained variables and the outcomes were examined using Pearson, polychoric and polyserial correlation coefficients. All assumptions of linear regression were examined, and there were no serious violations.
Three independent forward stepwise multiple linear regressions were performed to predict overall QOL. The 10 variables explaining the most variability per outcome were ranked by partial R2 order. Effect sizes were also estimated for these variables using t-values (Cohen, 1988; Liang et al, 1990), which is a quantitative similar to Cohen’s d. In the context of linear regression, the t-value corresponds to the difference in least-squares estimators divided by the standard error of the least-squares estimators. In an attempt to identify constructs with more consistent associations with overall QOL, the partial R2 rankings and effect sizes of the identified contributing variables were averaged per construct and across all three outcomes of overall QOL.
Stepwise multiple linear regression is an analytical approach that has the capacity to select a statistical model ‘when there is a large number of potential explanatory variables and no underlying theory on which to base the model selection’ (Pace, 2008). This automatism of the procedure has been previously described as its limitation. However, in this study, the Wilson and Cleary theoretical model of HQOL directed the selection of the variables included in the analyses. Also, this statistical approach has the advantage of preventing bias imposed by the investigators upon the selection of final model.
All statistical analyses were carried out using the Statistical Analysis Systems version 9.2.
Results
Description of the sample
Three thousand seven hundred fifty one patients were screened for eligibility. Of the 388 eligible patients, 203 patients (52.3%) consented to participate and completed the initial evaluation (Figure 2).
The average age was 63 years (±13) and 59.3% of participants were men. The most common primary tumour origins were the pancreas (22.6%), followed by lung (16.7%), and the colorectal tract (12.3%). Patient characteristics are presented in Table 1.
Sociodemographic information was collected from 157 patients who refused to participate. The age and gender distribution was similar in both the participants and the non-participants: the average age was of 67 years (±11.6) and 56.1% were men. The most common primary tumours sites in these patients were the lung (18.5%), followed by the pancreas (14.7%) and head or neck (14.0%). Participants and non-participants were similar (P-value=0.80) on perceived health rated on a scale of 0 to 10: 6.8 (±2.1) and 6.0 (±2.1), respectively.
The distributions of the three outcomes of overall QOL are presented in Figure 3. MQOL-Existential, MQOL-SIS and ESAS-QOL (rescored) all ranged from 0–10, 10 indicating best quality of life and 0 the worst. Participants rated their QOL similarly with all measures of overall QOL. The medians were 7.9 for MQOL-Existential and 7.0 for MQOL-SIS and ESAS-QOL. The interquartile ranges spanned 2 units for MQOL-Existential, 3 for MQOL-SIS and 4 for ESAS-QOL. Of the three outcomes of overall QOL, MQOL-Existential had a smaller distribution, not unexpected with a multi-item index.
Univariate associations
The screening of the associations between the 57 potential explanatory variables and each measure of overall QOL by simple linear regression led to the elimination of between 7 and 17 variables per outcome variable. Of the retained variables, 34 had statistically significant associations with all three outcomes of overall QOL, 7 with two outcomes and only 3 were associated with only one outcome of overall QOL.
The univariate correlation coefficients were consistent with expectations. The correlation coefficients between the contributor variables and the outcomes varied from 0.01 to 0.59.
Stepwise multiple linear regression analyses
Table 2 summarises the rankings in partial R2, from 1 (the most important) to 10 (the least important), of the first 10 variables identified by the three independent stepwise regressions, using the ranking for MQOL-Existential for the ordering of variables. Also presented are the effect sizes as measured by the t-test value.
When overall QOL was represented by MQOL-Existential, the variable with the highest partial R2 was general health perception (GHP) from the RAND-36, followed by the psychological domain of the MQOL (rank 2) and social support domain (rank 3). When overall QOL was represented by MQOL-SIS, GHP (from MQOL) retained the first rank, followed by the psychological domain of the MQOL (rank 2), and an item of the Faact measuring appetite (rank 3).
When overall QOL was represented by ESAS-QOL, a subscale measuring physical function in the MFI held the first rank; an item measuring fatigue from the ESAS was ranked second, followed by the social support domain of the MQOL (rank 3).
The last two columns of Table 2 present the averages of the R2 rankings and of the effect sizes. Using R2, the most important constructs contributing to overall QOL was social support and GHP (both with an average R2 ranking of 3.0), followed by psychological distress, and relatively closely by fatigue. Using effect sizes, the same general order of the most important contributors remained. However, the effect sizes identified social function as much an important contributor. Both R2 and effect sizes ranked physical function and symptoms profile in the same order. The two methods of average ranking produced statistically similar hierarchies when compared using the Wilcoxon signed-rank test (P=0.58).
We represented the hierarchy of contributors of the overall QOL in people with advanced cancer as a pyramid analogous to Maslow’s Hierarchy of Needs (Maslow, 1948) (Figure 4). As the pyramid identified needs, some constructs were modified to convey a positive meaning (‘fatigue’ was for instance modified to ‘energy’).
Discussion
Using multiple stepwise linear regression models, a large number of potential contributors to overall QOL were reduced to a manageable and interpretable clinical picture. Similar and sometimes different contributors were identified according to how the latent construct of overall QOL was represented.
Apart from random error, differences in the importance rankings by outcome undoubtedly arise from differences in the QOL outcomes themselves. Two outcomes were single items (MQOL-SIS and ESAS-QOL) and one was a subscale with a total score derived from averaging scores on 6 items (MQOL-Existential).
In the MQOL-SIS, the patient is asked to contemplate all aspects of his or her life (physical, emotional, social, spiritual and financial) (Cohen et al, 1997) and provide a value between 0 and 10. MQOL-Existential includes concerns regarding death, freedom, isolation and the meaning of life, as existential concerns have been demonstrated to be of great importance to people with a life-threatening illness and is under-represented in many measures assessing QOL (O’Connor et al, 1990; Fryback, 1993).
In contrast, ESAS-QOL is 1 of 10 visual analogue scales (VAS) describing how a person would best describe their health in the last 24 h. The health states include QOL and a variety of physical symptoms, usually of negative connotation such as fatigue, nausea, depression or pain (Bruera et al, 1991). It is therefore possible that although patients are asked to rate their general QOL, the context in which the item is asked is likely to influence the rating. Our study found that the contributing variables to the ESAS-QOL single-item were almost inversely ordered in terms of importance with respect to MQOL-Existential and MQOL-SIS.
We translated the findings from combining the results from the different the regression analyses into a ‘pyramid of needs’ mimicking Maslow’s Hierarchy of Needs (Maslow, 1948) to emphasise that these are key areas of everyday life and function that people with threatened health need in order to continue to view life as worth living (World Health Organisation, 2001).
Social support was found to be the most important contributor to overall QOL meaning that, on average, people with advanced cancer who that reported being supported by their social surrounding also reported higher levels of overall QOL. By the term ‘social support’, we refer mainly to the resources provided by other persons (Cohen and Syme, 1985). It has also been defined as the cognitive appraisal of being ‘reliably connected to significant others in a given social environment (Mathisen et al, 2007). Interestingly, it also fits with another identified contributor to overall QOL, social function. Social function can be defined as the actions and tasks required for basic and complex interactions with people in a contextually and socially appropriate manner (Cao et al, 2012). Therefore, the two concepts are closely related, as a socially functional individual will likely have a strong social support system in place that could be used as a coping mechanism and vice-versa.
Social support is becoming recognised as an important contributor of overall QOL in people with cancer. In a study on the prevalence and contributors to the unmet needs and their association with QOL, 296 men with advanced cancer were evaluated. Social support scores significantly predicted total overall QOL scores, to the same extent that psychological or physical symptoms did (Hwang et al, 2004). Recently, several studies have been recommending measuring social support as part of the assessment of people with cancer as they are key elements of their well-being (Gallagher and Vella-Brodrick, 2008; Hahn et al, 2010; McCabe and Cronin, 2011). The role of social support at end-of-life is recognised and is one of the key roles played by volunteers in hospice system (Pesut et al, 2012).
Other important contributors to overall QOL were fatigue, psychological distress, pain and physical function. This is consistent with the published literature. Pain, depression and fatigue are highly prevalent in cancer patients, and they often coexist. Laird et al (2011) recently identified that pain, depression and fatigue was an identifiable symptom cluster in a cohort of advanced cancer patients and is associated with reduced physical functioning. Similarly, a study on 1630 stage 3 and 4 Danish cancer patients identified the most prevalent symptoms contributing to a deterioration of QOL (Johnsen et al, 2009) as being fatigue (57%; severe 22%) followed by reduced role function, insomnia and pain (Johnsen et al, 2009). The importance of the prevalence of these symptoms is such that in 2003, the National Institute of Health convened a State-of-the-Science Conference on pain, depression and fatigue symptom management in people with cancer in order to identify directions for future research (Patrick et al, 2003).
The self-reported overall QOL found in our study was strikingly similar to other studies with comparable populations. Lowe et al (2009) evaluated 50 adult advanced cancer patients with estimated life expectancies of 3 to 12 months from outpatient palliative care clinic and home care. Patients obtained a mean QOL score of 7.4±1.4 on the MQOL-Existential and 6.1±2.0 on ESAS-QOL (scale reversed from the original score of 3.9±2.0) (Lowe et al, 2009). Similarly, 38 patients with advanced cancer were evaluated using MQOL-Existential and obtained a mean score of 7.9±1.2 (Sherman et al, 2006). The same can be observed for reports of the MQOL-SIS: Jones et al (2010) obtained a mean MQOL-SIS score of 6.1±1.4 when assessing 211 cancer patients admitted to an acute palliative care unit in a comprehensive cancer center.
This study included only patients with advanced disease, so the results may not be generalise to patients at the early stages of the disease. Regression approaches identify only those variables that, in the presence of all others, make a unique and direct contribution to the outcome, here overall QOL. A limitation is that variables which impact indirectly through other variables are not identified; nevertheless this approach provides a minimum portfolio of variables, which would be a starting in developing a more complex model requiring structural equation modelling (SEM). Another limitation of this approach is that the latent construct of overall QOL had to be modelled as different variables; SEM would allow the different representations of overall QOL to contribute statistically to a latent variable.
We demonstrated a novel way of using multivariate linear regressions to make sense of a large amount of information to a more manageable and clinically interpretable picture. However, the variation in the contributors to QOL has relevant implications for the clinical management of patients with advanced cancer. Depending on the instrument used, the focus of the interventions by the various health professionals would be different. Also, in the research setting, the choice of the instrument will greatly influence the ‘measured’ change in QOL secondary to the intervention(s) under study.
Social support is identified as the most important contributor to overall QOL in people with a recent diagnosis of advanced cancer. For health-care practitioners, this translates into assessing or asking patients recently diagnosed with cancer about their social networks and support and to arrange access for support when it is absent. The results also suggest paying particular attention to assessing and controlling physical function, fatigue, psychological distress, pain and gastrointestinal symptoms from the time of diagnosis. This would indicate that a team approach to measurement and care through the involvement of health-care professionals whose expertise lie in these domains (physical and occupational therapists, psychologists, social workers, nutritionists and palliative care physicians) would complement usual oncology care.
An interdisciplinary team approach, with a particular focus on physical function and fatigue, was found to be associated with improvement in overall QOL for patients with head and neck cancer (Eades et al, 2013). A recent clinical trial on the effect of early involvement of palliative care physicians and nurses in the care of patients with advanced lung cancer reported a significant improvement in overall QOL for the intervention group compared with patients receiving usual care (Temel et al, 2010). As the outcome for this study included items measuring physical function and fatigue, the effect may have been larger if the team had included health-care professionals with specialized expertise in those domains.
The involvement of health-care professionals with specific expertise in the management of cancer-related symptoms, psychological distress and loss of physical and social functions, supported by the integrated involvement of volunteers (Pesut et al, 2012), should be considered the new standard of care for patients with advanced cancer with decreased overall QOL. This is particularly important as fewer than 10% of oncology patients have been reported to receive psychosocial therapy (Lee et al, 2005b).
Modern health-care emphasises patient-centered care defined by a focus on outcomes that people notice and care about including, not only survival, but also function, symptoms and modifiable aspects of QOL (Patient-Centered Outcomes Research Insitute, 2013). Thus, the measurement and optimisation of the contributors to QOL, such as those identified in this study, would be necessary components of a patient-centered oncology program.
Change history
14 May 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bennett SJ, Perkins SM, Lane KA, Deer M, Brater DC, Murray MD (2001) Social support and health-related quality of life in chronic heart failure patients. Qual Life Res 10 (8): 671–682.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7 (2): 6–9.
Canadian Academy of Health Sciences (2010) Transforming Care for Canadians with Chronic Health Conditions: Put People First, Expect the Best, Manage for Results, Ottawa.
Cao MD, Sitter B, Bathen TF, Bofin A, Lonning PE, Lundgren S, Gribbestad IS (2012) Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed 25 (2): 369–378.
Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL (2002) Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 8 (3): 199–209.
Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. Academic Press: New York, NY, USA.
Cohen S, Syme SL (1985) Issues in the study and application of social support. In Cohen S, Syme SL (eds) Social Support and Health pp 3–41. Academic Press Inc.: Orlando, FL, USA.
Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K (1997) Validity of the McGill quality of life questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliative Med 11 (1): 3–20.
Cosby C, Holzemer WL, Henry SB, Portillo CJ (2000) Hematological complications and quality of life in hospitalized AIDS patients. AIDS Patient Care STDS 14 (5): 269–279.
Cunningham WE, Crystal S, Bozzette S, Hays RD (2005) The association of health-related quality of life with survival among persons with HIV infection in the United States. J Gen Intern Med 20 (1): 21–27.
Eades M, Murphy J, Carney S, Amdouni S, Lemoignan J, Jelowicki M, Nadler M, Chasen M, Gagnon B (2013) Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: review of clinical experience. Head Neck 35 (3): 343–349.
Food and Drug Administration (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4: 79.
Fryback PB (1993) Health for people with a terminal diagnosis. Nurs Sci Q 6 (3): 147–149.
Gallagher EN, Vella-Brodrick DA (2008) Social support and emotional intelligence as predictors of subjective well-being. Person Individual Differences 44 (7): 1551–1561.
Hahn EA, Devellis RF, Bode RK, Garcia SF, Castel LD, Eisen SV, Bosworth HB, Heinemann AW, Rothrock N, Cella D (2010) Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. Qual Life Res 19 (7): 1035–1044.
Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, McCaffrey DF, Fleishman JA, Crystal S, Collins R, Eggan F, Shapiro MF, Bozzette SA (2000) Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 108 (9): 714–722.
Heo S, Moser DK, Riegel B, Hall LA, Christman N (2005) Testing a published model of health-related quality of life in heart failure. J Card Fail 11 (5): 372–379, [pii].
Hwang SS, Chang VT, Cogswell J, Alejandro Y, Osenenko P, Morales E, Srinivas S, Kasimis B (2004) Study of unmet needs in symptomatic veterans with advanced cancer: incidence, independent predictors and unmet needs outcome model. J Pain Symptom Manage 28 (5): 421–432.
Johnsen AT, Petersen MA, Pedersen L, Groenvold M (2009) Symptoms and problems in a nationally representative sample of advanced cancer patients. Palliat Med 23 (6): 491–501.
Jones JM, Cohen SR, Zimmermann C, Rodin G (2010) Quality of life and symptom burden in cancer patients admitted to an acute palliative care unit. J Palliat Care 26 (2): 94–102.
Laird BJ, Scott AC, Colvin LA, McKeon AL, Murray GD, Fearon KC, Fallon MT (2011) Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage 42 (1): 1–11.
Lee DT, Yu DS, Woo J, Thompson DR (2005a) Health-related quality of life in patients with congestive heart failure. Eur J Heart Fail 7 (3): 419–422.
Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ (2005b) Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant 35 (1): 77–83.
Liang MH, Fossel AH, Larson MG (1990) Comparisons of five health status instruments for orthopedic evaluation. Med Care 28 (7): 632–642.
Lowe SS, Watanabe SM, Baracos VE, Courneya KS (2009) Associations between physical activity and quality of life in cancer patients receiving palliative care: a pilot survey. J Pain Symptom Manage 38 (5): 785–796.
Marrett LD, De P, Airia P, Dryer D (2008) Cancer in Canada in 2008. CMAJ 179 (11): 1163–1170.
Maslow AH (1948) Higher and lower needs. J Psychol 25: 433–436.
Mathisen L, Andersen MH, Veenstra M, Wahl AK, Hanestad BR, Fosse E (2007) Quality of life can both influence and be an outcome of general health perceptions after heart surgery. Health Qual Life Outcomes 5: 27.
McCabe C, Cronin P (2011) Issues for researchers to consider when using health-related quality of life outcomes in cancer research. Eur J Cancer Care 20 (5): 563–569.
Molzahn AE, Northcott HC, Hayduk L (1996) Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 5 (4): 426–432.
O’Connor AP, Wicker CA, Germino BB (1990) Understanding the cancer patient’s search for meaning. Cancer Nurs 13 (3): 167–175.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, (6): 649–655.
Osoba D (2007) Translating the science of patient-reported outcomes assessment into clinical practice. J Natl Cancer Inst Monogr, (37): 5–11.
Pace NL (2008) Independent predictors from stepwise logistic regression may be nothing more than publishable P values. Anesth Analg 107 (6): 1775–1778.
Patient-Centered Outcomes Research Insitute (2013) http://www.pcori.org/about/mission-and-vision/.
Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrisi AT III, Unutzer J, Vernon SW (2003) National institutes of health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, 15–17 July, 2002. J Natl Cancer Inst 95 (15): 1110–1117.
Pesut B, Hooper B, Lehbauer S, Dalhuisen M (2012) Promoting volunteer capacity in hospice palliative care: a narrative review. Am J Hospice Palliative Med e-pub ahead of print 31 December 2012.
Sherman DW, Ye XY, McSherry C, Parkas V, Calabrese M, Gatto M (2006) Quality of life of patients with advanced cancer and acquired immune deficiency syndrome and their family caregivers. J Palliat Med 9 (4): 948–963.
Sousa KH, Chen FF (2002) A theoretical approach to measuring quality of life. J Nurs Meas 10 (1): 47–58.
Sousa KH, Holzemer WL, Henry SB, Slaughter R (1999) Dimensions of health-related quality of life in persons living with HIV disease. J Adv Nurs 29 (1): 178–187.
Sousa KH, Kwok OM (2006) Putting Wilson and Cleary to the test: analysis of a HRQOL conceptual model using structural equation modeling. Qual Life Res 15 (4): 725–737.
Sousa KH, Williamson A (2003) Symptom status and health-related quality of life: clinical relevance. J Adv Nurs 42 (6): 571–577.
Straits-Troster K, Fields JA, Wilkinson SB, Pahwa R, Lyons KE, Koller WC, Troster AI (2000) Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn 42 (3): 399–416.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363 (8): 733–742.
Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklof A (2004) Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Qual Life Res 13 (8): 1369–1379.
Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273 (1): 59–65.
Wilson IB, Cleary PD (1996) Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Med Care 34 (6): 610–623.
Wilson IB, Cleary PD (1997) Clinical predictors of declines in physical functioning in persons with AIDS: results of a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 16 (5): 343–349.
World Health Organization (2001) International Classification of Functioning, Disability, and Health: ICF. World Health Organization: Geneva, Switzerland.
Acknowledgements
This research was supported by a grant from the Terry Fox Research Institute. B Gagnon is a recipient of ‘Chercheur-clinicien Boursier’ award from Fonds de recherche Santé Québec. We also thank Dr Neil MacDonald, Dr Lorenzo Ferri, Dr Peter Metrakos, Dr Linda O’Faria, Dr Catalin Mihalcioiu, Dr Victor Cohen, Dr Carmela Pepe, Dr David Small, Dr Chaudhury and Dr Prosanto, for their input or help in recruiting participants. We finally with to thank the participants and their families who gave their valuable time to participate in the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no conflict of interest.
Additional information
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Appendices
Appendix A
Reference List
Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett DR, Jr, Schmitz KH, Emplaincourt PO, Jacobs DR, Jr, Leon AS (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32 (9 Suppl): S498–S504
Benton AL, Hamsher KS, Varney NR, Spreen O (1983) Serial Digit Learning. In: Neuropsychological Assessment: A Clinical Manual Oxford University Press: New York, NY, USA.
Chang VT, Hwang SS, Feuerman M (2000) Validation of the edmonton symptom assessment scale. Cancer 88 (9): 2164–2171
Cohen SR, Boston P, Mount BM, Porterfield P (2001) Changes in quality of life following admission to palliative care units. Palliat Med 15 (5): 363–371
Cohen SR, Hassan SA, Lapointe BJ, Mount BM (1996a) Quality of life in HIV disease as measured by the McGill quality of life questionnaire. AIDS 10 (12): 1421–1427
Cohen SR, Mount BM (2000) Living with cancer: ‘good’ days and ‘bad’ days--what produces them? Can the McGill quality of life questionnaire distinguish between them? Cancer 89 (8): 1854–1865
Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K (1997) Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliative Med 11 (1): 3–20
Cohen SR, Mount BM, Strobel MG, Bui F (1995) The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9 (3): 207–219
Cohen SR, Mount BM, Tomas JJ, Mount LF (1996b) Existential well-being is an important determinant of quality of life. Evidence from the McGill Quality of Life Questionnaire. Cancer 77 (3): 576–586
de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H (1993) Measuring quality of life in stroke. Stroke 24 (2): 320–327
Fillion L, Gelinas C, Simard S, Savard J, Gagnon P (2003) Validation evidence for the French Canadian adaptation of the Multidimensional Fatigue Inventory as a measure of cancer-related fatigue. Cancer Nurs 26 (2): 143–154
Fransen M, Crosbie J, Edmonds J (1997) Reliability of gait measurements in people with osteoarthritis of the knee. PHYS Ther 77 (9): 944–953
Goodyear MDE, Fraumeni MA (1996) Incorporation Quality of Life Assessment into Clinical Cancer Trials. In Spilker B (ed) pp Quality of Life and Pharmacoeconomics in Clinical Care, 1003–1013. Lippincott-Raven Publishers: Pennsylvania, PA, USA
Hays RD, Sherbourne CD, Mazel RM (1993) The RAND-36-Item Health Survey 1.0. Health Econ 2 (3): 217–227
Holden MK, Gill KM, Magliozzi MR (1986) Gait Assessment for Neurologically Impaired Patients: Standards for Outcome Assessment. Phys Ther 66 (10): 1530–1539
Meek PM, Nail LM, Barsevick A, Schwartz AL, Stephen S, Whitmer K, Beck SL, Jones LS, Walker BL (2000) Psychometric testing of fatigue instruments for use with cancer patients. Nursing Res 49 (4): 181–190
Nakamura R, Handa T, Watanabe S, Morohashi I (1988) Walking cycle after stroke. Tohoku J Exp Med 154 (3): 241–244
Nekolaichuk C, Watanabe S, Beaumont C (2008) The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991–2006) Palliat Med 22 (2): 111–122
Norum J (1996) Quality of life (QoL) measurement in economical analysis in cancer: A comparison of the EuroQol questionnaire, a simple QoL-scale and the global QoL measure of the EORTC QLQ-C30. Oncol Rep 3 787–791
O’Carroll RE, Conway S, Ryman A, Prentice N (1997) Performance on the delayed word recall test (DWR) fails to differentiate clearly between depression and Alzheimer’s disease in the elderly. Psychol Med 27 (4): 967–971
Podsiadlo D, Richardson S (1991) The timed up and go—a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39 (2): 142–148
Poissant L, Mayo NE, Wood-Dauphinee S, Clarke AE (2003) The development and preliminary validation of a preference-based stroke index (PBSI) Health Qual Life Outcomes 1 43, doi:10.1186/1477-7525-1-43 [doi];1477-7525-1-43 [pii]
Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von RJ, Leslie WT (2000) Re-validation and shortening of the functional assessment of anorexia/cachexia therapy (FAACT) questionnaire. Qual Life Res 9 (10): 1137–1146
Richardson LA, Jones GW (2009) A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 16 (1): 55
Schneider RA (1998) Reliability and validity of the multidimensional fatigue inventory (MFI-20) and the Rhoten fatigue scale among rural cancer outpatients. Cancer Nursing 21 (5): 370-373
Smets EM, Garssen B, Bonke B, de Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (3): 315–325
Solway S, Brooks D, Lacasse Y, Thomas S (2001) A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119 (1): 256–270
Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL (2001a) CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exercise 33 (7): 1126–1141
Stewart AL, Verboncoeur CJ, McLellan BY, Gillis DE, Rush S, Mills KM, King AC, Ritter P, Brown BW, Jr., Bortz WM (2001b) Physical activity outcomes of CHAMPS II: a physical activity promotion program for older adults. J Gerontol Ser A Biol Sci Med Sci 56 (8): M465–M470
Venturini, A, Wilford, C, Finch, L, Spetsieris, P, and Rubinoff, S 1995. The Timed Up and Go: Reliability and Validity in an Acute Neurological Population. World Congress of Physiotherapy (Abstract).
Wood-Dauphinee, S, Mayo, N, Jung, H, and Shen, N. Does the SF-36 reflect changes in the health of people with stroke? 5th Annual Conference of the International Society for Quality of Life Research: 15–17 November 1998, Baltimore, MD, USA. [Abstract]. Quality Life Res. 7[7], 561–682. 1998.
Appendix B
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
M RodrÃguez, A., Mayo, N. & Gagnon, B. Independent contributors to overall quality of life in people with advanced cancer. Br J Cancer 108, 1790–1800 (2013). https://doi.org/10.1038/bjc.2013.146
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2013.146
Keywords
This article is cited by
-
Quality of care and quality of life as experienced by patients with advanced cancer of a rare tumour type: results of the multicentre observational eQuiPe study
Journal of Cancer Survivorship (2023)
-
Impact of reconceptualization response shift on rating of quality of life over time among people with advanced cancer
Supportive Care in Cancer (2018)
-
Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan
Breast Cancer Research and Treatment (2017)
-
The longitudinal course of depression symptomatology following a palliative rehabilitation program
Quality of Life Research (2017)
-
Reported distress in patients living with advanced cancer: changes pre-post interdisciplinary palliative rehabilitation
Supportive Care in Cancer (2017)